Race Oncology Ltd has released a press release.
Second independent study shows Bisantrene inhibits FTO
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Racura Oncology
- Race Strategic Update March 2021
- Race Initiates Extramedullary AML Preclinical Study
- Race Initiates FTO Directed Kidney Cancer Preclinical Study
- Race Initiates FTO Melanoma Preclinical Study
- S&P DJI Announces March 2021 Quarterly Rebalance
Later from Racura Oncology
- Race Initiates Heart Safety Preclinical Study for Bisantrene
- Race investor briefing & updated presentation
- Placement closes oversubscribed-Bonus Option Issue launched
- Prospectus
- Contract to Commence Phase 2 Extramedullary AML Trial
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology